| Detected | Trial | Change |
|---|---|---|
| 2026-06-05 | NCT07528352 External Beam Radiotherapy Followed by Bispecific Antibody Therapy for… |
Recruitment opened |
| 2026-06-05 | NCT07528352 External Beam Radiotherapy Followed by Bispecific Antibody Therapy for… |
date change Primary completion pushed: 2030-05 -> 2030-06 |
| 2026-06-05 | NCT07528352 External Beam Radiotherapy Followed by Bispecific Antibody Therapy for… |
date change Completion pushed: 2031-05 -> 2031-06 |
| 2026-06-05 | NCT06536049 Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell… |
date change Primary completion pushed: 2026-12-31 -> 2027-08-31 |
| 2026-06-05 | NCT06536049 Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell… |
date change Completion moved earlier: 2028-12-31 -> 2027-10-31 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-15 | NCT07588698 Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06191744 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral… | Follicular Lymphoma (FL) | Recruiting |
| NCT06508658 | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to… | Diffuse Large B-Cell Lymphoma | Active, Not Recruiting |
| NCT07226752 | A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in… | Diffuse Large B-Cell Lymphoma | Active, Not Recruiting |
| NCT04628494 | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in… | Diffuse Large B-cell Lymphoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT07108998 | Study of Epcoritamab as a Consolidation Therapy in CLL/SLL | CLL/SLL | Recruiting |
| NCT06563596 | Epco, Zanu, Ritux for R/R FL or MZL | Follicular Lymphoma | Recruiting |
| NCT06811272 | Outpatient Epcoritamab as 2L in NTE R/R DLBCL | Relapsed Large B-cell Lymphoma | Recruiting |
| NCT06919939 | Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large… | Large B-cell Lymphoma | Recruiting |
| NCT06510361 | Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront… | Lymphoma | Recruiting |
| NCT06510491 | Epcoritamab in Previously Treated WM | Waldenstrom Macroglobulinemia | Recruiting |
| NCT07218510 | Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT06931652 | Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With… | Primary CNS Lymphoma (PCNSL) | Recruiting |
| NCT07451652 | Low Dose Epcoritamab Plus GemOx in R/R DLBCL | Relapsed/Refractory Diffuse Large B Cell Lymphoma | Recruiting |
| NCT07097363 | Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin… | B-Cell Non-Hodgkin Lymphoma | Recruiting |
| NCT07365306 | Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before… | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recruiting |
| NCT05848765 | Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy | Relapsed Follicular Lymphoma | Recruiting |
| NCT05852717 | Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP)… | Large Cell Lymphoma, Diffuse | Recruiting |
| NCT06045247 | Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail… | Large B-cell Lymphoma | Recruiting |
| NCT05783609 | Epcoritamab and Rituximab for First-line Follicular Lymphoma | Follicular Lymphoma | Recruiting |
| NCT06458439 | Epcoritamab-CAR T Cells for Large B-cell Lymphomas | Lymphoma, Non-Hodgkin | Recruiting |
| NCT05283720 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC)… | Non-Hodgkin Lymphoma | Recruiting |
| NCT06723457 | Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed… | Recurrent B-Cell Non-Hodgkin Lymphoma | Active, Not Recruiting |
| NCT06112847 | Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma | Follicular Lymphoma | Active, Not Recruiting |
| NCT07588698 | Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma | Non-Hodgkin's B-cell Lymphoma | Not Yet Recruiting |
| NCT05660967 | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse… | Diffuse Large B-Cell Lymphoma | Active, Not Recruiting |